Literature DB >> 27871804

Additional surgical resection after endoscopic mucosal dissection for early gastric cancer: A medium-sized hospital's experience.

Bunzo Nakata1, Masashige Tendo2, Masatsugu Okuyama3, Kenichi Nakahara3, Hirotaka Ishizu3, Go Masuda2, Tomohiro Lee2, Takeshi Hori2, Masahiko Ohsawa4, Hiroshi Sato3, Tetsuro Ishikawa2.   

Abstract

PURPOSE: In Japan, the majority of early gastric cancers (EGCs) are now treated with endoscopic submucosal dissection (ESD). Patients with non-curative lesions treated by ESD are advised to undergo additional surgical resection (ASR) based on guidelines from the Japan Gastroenterological Endoscopy Society (JGES) and Japanese Gastric Cancer Association (JGCA). However, many studies have demonstrated that residual cancer and lymph node metastasis are only rarely found in ASR specimens. Here we retrospectively analyzed the conditions that could enable the avoidance of unnecessary ASR.
METHODS: The ESD data for 114 absolute indication lesions and 26 lesions of expanded indication lesions were analyzed. The indications and the curability were evaluated according to the JGES/JGCA guidelines.
RESULTS: The rates of non-curative resection and ASR were significantly higher in the expanded indication group compared to the absolute indication group (26.9% and 19.2% vs. 7.9% and 0.9%, respectively). ASR was performed for six patients. Three of their ARS specimens contained neither residual cancer nor lymph node metastasis, and the pathological findings of the preceding ESD specimens deviated slightly from the curative criteria defined by the guidelines. The conditions of the lesions that did not meet the curative criteria were as follows: (1) sm1 invasion of undifferentiated-type lesion <10 mm dia., (2) 21-25 mm dia. mucosal undifferentiated-type lesion, or (3) peacemeal resection with a horizontal margin positive for the mucosal differentiated-type.
CONCLUSIONS: These data suggest that a close follow-up without ASR might be appropriate for patients in the above-mentioned three categories after non-curative ESD for EGC.
Copyright © 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Additional surgical resection; Early gastric cancer; Endoscopic submucosal gastrectomy; Lymph node metastasis; Residual cancer

Mesh:

Year:  2016        PMID: 27871804     DOI: 10.1016/j.ijsu.2016.11.084

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  4 in total

1.  Long-term outcomes of patients with early gastric cancer found to have lesions for which endoscopic treatment is not indicated on histopathological evaluation after endoscopic submucosal dissection.

Authors:  Takafumi Yano; Kenji Ishido; Satoshi Tanabe; Takuya Wada; Mizutomo Azuma; Natsuko Kawanishi; Sakiko Yamane; Akinori Watanabe; Chikatoshi Katada; Wasaburo Koizumi
Journal:  Surg Endosc       Date:  2017-08-24       Impact factor: 4.584

2.  Additional laparoscopic gastrectomy after noncurative endoscopic submucosal dissection for early gastric cancer: A single-center experience.

Authors:  Yan-Tao Tian; Fu-Hai Ma; Gui-Qi Wang; Yue-Ming Zhang; Li-Zhou Dou; Yi-Bin Xie; Yu-Xin Zhong; Ying-Tai Chen; Quan Xu; Dong-Bing Zhao
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

3.  Factors associated with overall survival in early gastric cancer patients who underwent additional surgery after endoscopic submucosal dissection.

Authors:  Zhi Zheng; Fan-Di Bu; Hao Chen; Jie Yin; Rui Xu; Jun Cai; Jun Zhang; Hong-Wei Yao; Zhong-Tao Zhang
Journal:  World J Clin Cases       Date:  2021-04-06       Impact factor: 1.337

4.  Machine Learning Improves the Prediction Rate of Non-Curative Resection of Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer.

Authors:  Hae-Ryong Yun; Cheal Wung Huh; Da Hyun Jung; Gyubok Lee; Nak-Hoon Son; Jie-Hyun Kim; Young Hoon Youn; Jun Chul Park; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee
Journal:  Cancers (Basel)       Date:  2022-07-31       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.